Cargando…
Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
Immune checkpoint inhibitors (ICIs) that target cytotoxic T lymphocyte antigen 4, programmed cell death-1, and PD-ligand 1 have revolutionized cancer treatment, achieving unprecedented efficacy in multiple malignancies. ICIs are increasingly being used in early cancer settings and in combination wit...
Autores principales: | Zhou, Yu-Wen, Zhu, Ya-Juan, Wang, Man-Ni, Xie, Yao, Chen, Chao-Yue, Zhang, Tao, Xia, Fan, Ding, Zhen-Yu, Liu, Ji-Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897286/ https://www.ncbi.nlm.nih.gov/pubmed/31849640 http://dx.doi.org/10.3389/fphar.2019.01350 |
Ejemplares similares
-
Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022) -
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
por: Chen, Chenxin, et al.
Publicado: (2021) -
Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect
por: Huang, Junqi, et al.
Publicado: (2022) -
Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017) -
Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)